Novo Nordisk (NVO) unveiled new data from the phase 3 FRONTIER4 extension study evaluating the long-term safety and efficacy of investigational denecimig subcutaneous prophylaxis in children, adolescents, and adults with hemophilia A, with or without inhibitors, across a range of dosing frequencies including once-monthly, once-every-two-weeks, and once-weekly administration. These results and other data across Novo Nordisk’s hemophilia portfolio were presented at the International Society on Thrombosis and Haemostasis, ISTH, Congress in Paris. Interim analyses from the open-label, phase 3 FRONTIER4 long-term safety and efficacy study included 426 people with hemophilia A aged 1 year and older on denecimig prophylaxis. For the primary study endpoint of safety, denecimig was found to be consistent with findings previously shared from the FRONTIER research program. Injection-site reactions were reported at low rates in children and in adolescents and adults, and all were mild and transient. No clinical evidence of neutralizing antibodies was observed. For the secondary study endpoints of efficacy, estimated mean annualized bleeding rates were consistent with findings from the FRONTIER research program across all dosing regimens and regardless of inhibitor status. Across all doses, approximately 71% of adults and adolescents and 89% of children experienced zero treated bleeds while receiving denecimig.TipRanks Welcomes a New ETF – NYSE:RANK TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE. RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.